Journal of Thrombosis and Thrombolysis

, Volume 34, Issue 1, pp 73–78

ADAMTS13 and Von Willebrand factor in patients undergoing hemodialysis

  • Danyelle R. A. Rios
  • Maria G. Carvalho
  • Roberta C. Figueiredo
  • Cláudia N. Ferreira
  • Valério L. Rodrigues
  • Regina A. Souza
  • Ana C. Simões e Silva
  • Ana Paula Fernandes
  • Karina B. Gomes
  • Luci M. S. Dusse
Article

DOI: 10.1007/s11239-012-0682-1

Cite this article as:
Rios, D.R.A., Carvalho, M.G., Figueiredo, R.C. et al. J Thromb Thrombolysis (2012) 34: 73. doi:10.1007/s11239-012-0682-1

Abstract

Hemodialysis (HD) is associated with increasing thrombotic trend. Vascular access thrombosis (VAT) increases morbidity in HD patients. The aim of this study was to evaluate ADAMTS13 and VWF plasma levels from patients undergoing HD as putative biomarkers of the hypercoagulability state, as well the association between these markers and VAT occurrence. This study included 195 patients on HD for more than 6 months. HD patients were allocated into two groups according to the occurrence or not of previous episode of VAT; HD with VAT (N = 46) and HD without VAT (N = 149). ADAMTS13 and VWF were performed by ELISA. There was no significant difference between HD patients with and without VAT for ADAMTS13 and VWF levels. However, VWF levels were higher (P < 0.001) and ADAMTS13 were lower (P < 0.001) in HD patients, comparing to the control group composed by healthy subjects without kidney disease, age and sex-matched (N = 80). Taken together our data suggest a potential role of the kidneys function compromised on ADAMTS13 synthesis or metabolism, regardless other known sources of ADAMTS13. The imbalance between ADAMTS13 and VWF levels does not explain the development of VAT in HD patients by itself, although it should contribute for the hypercoagulability state. Therefore, additional studies to identify other risk factors are warranted and essential for better management of HD patients.

Keywords

Hemodialysis ADAMTS13 VWF Vascular access thrombosis 

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Danyelle R. A. Rios
    • 1
  • Maria G. Carvalho
    • 1
  • Roberta C. Figueiredo
    • 2
  • Cláudia N. Ferreira
    • 1
  • Valério L. Rodrigues
    • 5
  • Regina A. Souza
    • 3
  • Ana C. Simões e Silva
    • 4
  • Ana Paula Fernandes
    • 1
  • Karina B. Gomes
    • 1
  • Luci M. S. Dusse
    • 1
  1. 1.Department of Clinical and Toxicological Analysis, Faculty of PharmacyUniversidade Federal de Minas GeraisBelo HorizonteBrazil
  2. 2.Department of Public Healthy, Faculty of MedicineUniversidade Federal de Minas GeraisBelo HorizonteBrazil
  3. 3.Clinical Hospital of Universidade Federal de Minas GeraisUniversidade Federal de Minas GeraisBelo HorizonteBrazil
  4. 4.Department of Pediatric, Faculty of MedicineUniversidade Federal de Minas GeraisBelo HorizonteBrazil
  5. 5.Instituto Mineiro de NefrologiaBelo HorizonteBrazil